Immune checkpoint inhibitors (ICIs), such as cytotoxic T lymphocyte-associated protein 4 (CTLA-4) inhibitors and antibodies targeting programmed cell death protein 1 (PD-1) or its ligand PD-L1, have revolutionized the treatment of NSCLC [10]. Here, PDCD1 is linked to non-small cell lung carcinoma.